Arslan Cagatay, Isik Metin, Guler Gulnur, Kulac Ibrahim, Solak Mustafa, Turker Burcu, Ozisik Yavuz, Altundag Kadri
Department of Medical Oncology, Izmir Tepecik Research and Training Hospital, Izmir, Turkey.
Am Surg. 2012 Sep;78(9):992-9.
Recently, it has been shown that androgen and androgen receptor (AR) also have an important role in the pathogenesis and outcome of breast cancer. However, their significance in different subtypes of breast cancer is still under investigation. The aim of this study was to study the effects of AR on clinicopathological features and prognosis in patients with estrogen and progesterone receptor (ER/PR)-negative, HER2-positive breast cancer. Tumor paraffin-embedded blocks from archives were used for AR study. Data of patients with ER/PR-negative and HER2-positive breast cancer diagnosed at our institute between 1999 and 2010 were recorded and analyzed retrospectively. We studied 36 patients with ER/PR-negative and HER2-positive breast cancer for AR status. Sixteen of them (44.4%) showed AR positivity. The median age was 47 and 56 years for AR-negative and -positive patients, respectively (P = 0.03). The number of postmenopausal patients was higher in the AR-positive than -negative group (56 vs 30%) (P = 0.01). Other demographic data were similar in both group. Histopathological parameters and tumor and nodal stages were similar in both groups. Trastuzumab treatment was more frequently given to AR-positive than -negative patients (94 vs 44%) (P = 0.01). Median follow-up was 47.1 and 34.7 months in AR-negative and -positive groups, respectively (P = 0.03). Relapse occurred in six and four patients in AR-negative and -positive groups. Median progression-free survival (PFS) was similar in both groups (15.7 and 19.6 months in AR-negative and -positive patients, respectively; P = 0.56). Two patients died at 23.4 and 46 months of follow-up in the AR-negative group. There were no deaths in the AR-positive group. Overall survival analyses were not done as a result of an unmet number of events. Median PFS was similar in AR-positive and -negative in that group of patients with ER/PR-negative and HER2-positive breast cancer. However AR-positive patients were more frequently postmenopausal, older, and positive for lymphovascular space invasion. More frequently applied trastuzumab in the AR-positive group might have an effect on the similarity of PFS between the two groups. Studies with higher numbers in this subset of patients with breast cancer will give more robust data.
最近的研究表明，雄激素和雄激素受体（AR）在乳腺癌的发病机制和预后中也发挥着重要作用。然而，它们在不同亚型乳腺癌中的意义仍在研究中。本研究旨在探讨AR对雌激素和孕激素受体（ER/PR）阴性、HER2阳性乳腺癌患者临床病理特征及预后的影响。利用存档的肿瘤石蜡包埋块进行AR研究。回顾性记录并分析了1999年至2010年在我院诊断为ER/PR阴性和HER2阳性乳腺癌患者的数据。我们研究了36例ER/PR阴性和HER2阳性乳腺癌患者的AR状态。其中16例（44.4%）显示AR阳性。AR阴性和阳性患者的中位年龄分别为47岁和56岁（P = 0.03）。AR阳性组绝经后患者数量高于阴性组（56%对30%）（P = 0.01）。两组的其他人口统计学数据相似。两组的组织病理学参数以及肿瘤和淋巴结分期相似。AR阳性患者比阴性患者更频繁接受曲妥珠单抗治疗（94%对44%）（P = 0.01）。AR阴性和阳性组的中位随访时间分别为47.1个月和34.7个月（P = 0.03）。AR阴性和阳性组分别有6例和4例患者复发。两组的中位无进展生存期（PFS）相似（AR阴性和阳性患者分别为15.7个月和19.6个月；P = 0.56）。AR阴性组有2例患者在随访23.4个月和46个月时死亡。AR阳性组无死亡病例。由于事件数量未满足要求，未进行总生存分析。在ER/PR阴性和HER2阳性乳腺癌患者组中，AR阳性和阴性患者的中位PFS相似。然而，AR阳性患者绝经后更常见、年龄更大且淋巴管浸润阳性。AR阳性组更频繁应用曲妥珠单抗可能对两组PFS的相似性产生影响。对这一乳腺癌患者亚组进行更多病例数的研究将提供更可靠的数据。
